Scarica l'app Stockscreener
71.61
1.40%
-1.11
Dopo l'orario di chiusura:
71.58
-0.03
-0.04%
Arcellx Inc Borsa (ACLX) Ultime notizie
US Bancorp DE Has $462,000 Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ACLX June 20th Options Begin Trading - Nasdaq
Arcellx (NASDAQ:ACLX) Shares Gap Up – Time to Buy? - Defense World
Principal Financial Group Inc. Trims Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Myesha Lacy - IR Impact
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates - Simply Wall St
We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn - Yahoo Finance
New York State Common Retirement Fund Has $1.55 Million Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
HC Wainwright Predicts Arcellx’s Q1 Earnings (NASDAQ:ACLX) - Defense World
Optimistic Buy Rating for Arcellx Inc: Promising CAR-T Therapy and Strong Financial Position Highlighted - TipRanks
Arcellx Reports Promising 2024 Financial and Clinical Progress - MSN
Arcellx (NASDAQ:ACLX) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
State of New Jersey Common Pension Fund D Purchases New Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Why Arcellx Inc Stocks Are on the Rise - TipRanks
Arcellx Inc’s Anito-cel: Anticipated Market Leader with Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position - TipRanks
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating - TipRanks
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Rhumbline Advisers - Defense World
Rami Elghandour Sells 38,300 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - BioSpace
Arcellx earnings missed by $0.31, revenue fell short of estimates - Investing.com UK
Arcellx reports FY24 EPS ($2.00), consensus ($1.50) - TipRanks
Arcellx CEO Rami Elghandour sells $2.38 million in stock By Investing.com - Investing.com South Africa
Can Arcellx's 97% Response Rate in Multiple Myeloma Transform Treatment Landscape? - StockTitan
Arcellx CEO Rami Elghandour sells $2.38 million in stock - Investing.com
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - BioSpace
State of New Jersey Common Pension Fund D Buys Shares of 23,966 Arcellx, Inc. (NASDAQ:ACLX) - Defense World
arcellx director Kavita Patel sells $94,740 in common stock By Investing.com - Investing.com South Africa
Arcellx chief medical officer sells $647,772 in stock By Investing.com - Investing.com South Africa
arcellx director Kavita Patel sells $94,740 in common stock - Investing.com India
(ACLX) Investment Analysis and Advice - Stock Traders Daily
Allspring Global Investments Holdings LLC Sells 1,948 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx chief medical officer sells $647,772 in stock - Investing.com India
The Biotech Boom: Is Arcellx the Hidden Gem Investors Need? - Bit Perfect Solutions
The Untapped Potential of Biotech: Is Now the Time to Invest? - DSA
Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? - MSN
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Arcellx (ACLX) Expected to Announce Earnings on Wednesday - MarketBeat
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN
Is Arcellx (ACLX) Poised to Capture Significant Market Share? - MSN
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World
5.68%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):